Novo Nordisk Secures EMA Approval for Wegovy Delivery Flexibility
Bagsværd, Denmark | April 9, 2026 Novo Nordisk has announced that the European Medicines Agency (EMA) has approved an...
Novo Nordisk
Advertisement
Novo Nordisk Awiqli FDA Approval Weekly Insulin
Bagsværd, Denmark – March 27, 2026 Novo Nordisk announced that the U.S. FDA has approved Awiqli® (insulin icodec-abae), the...
Novo Nordisk Wegovy HD Approved with 20% Weight Loss
BAGSVÆRD, Denmark, March 19, 2026 Novo Nordisk A/S announced that the U.S. Food and Drug Administration (FDA) has approved...
Novo Nordisk, Vivtex Partner on Oral Obesity Drugs
February 25, 2026 – Bagsværd, Denmark & Boston, Massachusetts, USA Novo Nordisk and Vivtex Corporation have announced a strategic...
China Supreme Court Upholds Novo Nordisk Semaglutide Patent
BAGSVAERD, DENMARK | December 31, 2025 — Novo Nordisk announced that China’s Supreme People’s Court has upheld the validity...
Advertisements
Novo Nordisk’s Amycretin Shows Strong Phase 2 Diabetes Results
Bagsværd, Denmark, Nov. 25, 2025 — Novo Nordisk has announced positive Phase 2 clinical trial results for amycretin, a...
Novo Nordisk Reshapes Leadership Structure Following EGM Vote
Dateline: November 14, 2025 — Bagsværd, DenmarkNovo Nordisk A/S announced a series of major Board of Directors changes following...
Emcure Partners with Novo Nordisk to Bring Semaglutide to India
Bengaluru, November 10, 2025 — Global diabetes-care leader Novo Nordisk India has entered into a strategic partnership with Emcure...
Pfizer Challenges Novo Nordisk’s Proposal to Acquire Metsera
New York, October 30, 2025 — Pfizer Inc. (NYSE: PFE) has issued a strong response to what it calls...
Novo Nordisk: Ozempic® Cuts Mortality and CV Events in Real-World Study
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
Advertisement
